Protara Therapeutics announces results from Phase 2 ADVANCE-2 trial

Protara Therapeutics (TARA) announced results from its ongoing Phase 2 open-label ADVANCED-2 trial. The trial is assessing intravesical TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer, NMBIC, patients with carcinoma in situ or CIS who are Bacillus Calmette-Guerin-Unresponsive or BCG-Naive. The complete response, CR, rate across BCG exposures was 72% at six months and 70% at any time with 100% of patients maintaining a CR from three months to six months. In addition, two of three patients maintained a CR at nine months. These results will be featured today during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology, SUO, in Dallas, Texas.